Background: Non-small cell lung cancer (NSCLC) is one of the most leading cause of
tumor related mortality worldwide. However, the prognosis of NSCLC remained to be poor and
the mechanisms remained to be further investigated.
Objective: This study aimed to evaluate whether GPRIN1 could be a potential biomarker for
Methods: The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) and GEO
database(http://www.ncbi.nlm.nih.gov/geo) were used to analyze the GPRIN1 expression between
normal and human cancers. The protein-protein interaction among centromere proteins was
determined using STRING database (http://www.bork.emblheidelberg.de/STRING/). GraphPad
Prism 5.0 software was utilized for the independent and paired samples’ t-test or ANOVA to
analyze the difference of GPRIN1 expression between two groups.
Results: This study showed GPRIN1 was overexpressed and correlated to shorter OS time in
human cancers. In NSCLC, we found that GPRIN1 was up-regulated in NSCLC samples compared
to normal lung tissues by analyzing TCGA and GEO datasets. Bioinformatics analysis indicated
that this gene was involved in regulating cancer proliferation and metabolism. Finally, we
identified key targets of GPRIN1 in NSCLC by constructing PPl networks, including MCM3,
KIF20A, UHRF1, BRCA1, KIF4A, HMMR, KIF18B, KIFC1, ASPM, and NCAPG2.
Conclusion: These analyses showed GPRIN1 could act as a prognosis biomarker in patients with